President Trump Signs Executive Order to Accelerate Psychedelic Medical Research

2026-04-19

The BareStory

On Saturday, President Donald Trump signed an executive order in the Oval Office aimed at accelerating the research and approval of psychedelic-based therapies. The directive specifically targets experimental treatments involving substances such as ibogaine to address conditions including depression, addiction, and post-traumatic stress disorder.

Trump stated the order is intended to provide new treatment options for veterans experiencing severe mental health issues. According to the president, the directive will remove bureaucratic obstacles and instruct the Food and Drug Administration (FDA) to expedite the review of certain psychedelics. Under the executive action, the federal government will make a $50 million investment into research and open a pathway for severely ill patients to access ibogaine through the FDA's Right To Try rule. The directive also establishes a framework for the expedited rescheduling of any psychedelics that eventually secure FDA approval.

During the event, FDA Commissioner Marty Makary announced the agency will begin allowing researchers to conduct human trials on ibogaine and will add three psychedelics to a priority review pilot program. The signing was attended by multiple health officials and public figures, including Health and Human Services Secretary Robert F. Kennedy Jr. and podcaster Joe Rogan, whom Trump stated privately lobbied him on the matter.

Ibogaine and several other psychedelics are currently classified federally as Schedule I controlled substances. While some studies suggest potential benefits for treatment-resistant mental health conditions, scientific evidence remains limited primarily to small observational studies, animal testing, and early human trials. Researchers caution that ibogaine carries severe safety risks, including potentially fatal irregular heart rhythms, emphasizing that such experimental treatments require careful medical monitoring and large-scale clinical trials before they can be deemed safe or effective.

Left Perspective

Subverting Independent Scientific Rigor
Shielding Vulnerable Patient Populations
Politicizing Federal Drug Classifications

Right Perspective

Honoring Essential Civic Obligations
Restoring Individual Medical Liberty
Combating Social Order Decay

Left Perspective

• Subverting Independent Scientific Rigor Government accountability requires regulatory agencies to operate transparently and free from private influence. By using an executive order to direct the FDA based on private lobbying from media figures like Joe Rogan and politicians like Robert F. Kennedy Jr., this maneuver fundamentally undermines institutional integrity. The prioritization of executive directives over established scientific protocols threatens the independence of federal health agencies.

• Shielding Vulnerable Patient Populations Protecting at-risk populations demands that experimental treatments undergo rigorous testing before widespread access is permitted. Ibogaine carries documented, severe safety risks—including potentially fatal irregular heart rhythms—yet the administration is fast-tracking it for veterans and severely ill patients. Accelerating access through the "Right To Try" rule circumvents necessary large-scale clinical trials, effectively using desperate demographics as test subjects for unproven substances.

• Politicizing Federal Drug Classifications The established framework for categorizing Schedule I controlled substances relies on comprehensive, peer-reviewed evidence rather than executive mandates. Forcing a pathway to rapidly reschedule these psychedelics and injecting a $50 million federal investment based merely on small observational studies and animal testing sets a dangerous precedent. This approach risks dismantling the objective, evidence-based methodology designed to prevent the premature commercialization of dangerous narcotics.

Right Perspective

• Honoring Essential Civic Obligations Preserving the national fabric requires the state to fulfill its absolute highest duty to those who maintain its security. Trump’s executive order treats the mental health crisis among veterans suffering from PTSD and depression as an urgent civic priority that supersedes standard administrative delays. By aggressively clearing bureaucratic obstacles and securing a $50 million investment, this framework prioritizes the immediate survival of service members over the inertia of federal agencies.

• Restoring Individual Medical Liberty Systemic stability is maintained when citizens retain fundamental agency over their own lives, rather than submitting to excessive state intervention. Expanding the FDA's Right To Try rule to include ibogaine restores critical decision-making power to severely ill patients who have exhausted conventional options. FDA Commissioner Marty Makary’s authorization of human trials reflects a shift away from bureaucratic gatekeeping, allowing citizens to assume personal responsibility for their medical risks.

• Combating Social Order Decay Untreated addiction and severe mental illness actively degrade community stability and national cohesion. By prioritizing three psychedelics for rapid review and establishing a framework for their expedited rescheduling, the administration treats these afflictions as direct threats to social order that require decisive, pragmatic intervention. Engaging advocates like Robert F. Kennedy Jr. and Joe Rogan demonstrates a willingness to adopt outside-the-box solutions to rapidly stabilize a population the medical establishment has failed to cure.

How it may affect me

As a U.S. reader:

• Severely ill patients and veterans will have short-term avenues to access experimental psychedelic therapies like ibogaine through the Right To Try rule before standard large-scale clinical trials are completed

• Individuals utilizing these newly available experimental treatments will assume personal responsibility for severe medical risks, including potentially fatal irregular heart rhythms, with less traditional regulatory oversight

• Taxpayers will fund a $50 million federal investment directed toward accelerating early human trials and observational research into psychedelics for treating depression, addiction, and post-traumatic stress disorder

• The federal drug approval process will undergo immediate operational shifts as the FDA bypasses standard administrative timelines to prioritize the review of specific psychedelics based on executive directives

• In the long term, the public may see certain psychedelics rapidly reclassified from their current federal restriction as Schedule I controlled substances if they secure FDA approval under the new expedited framework

President Trump Signs Executive Order to Accelerate Psychedelic Medical Research

The BareStory

Left Perspective

Right Perspective

How it may affect me

Read the story at